Pharmaceuticals company Gujarat Themis Biosyn announced Q4FY23 & FY23 results: Q4FY23: Revenue from Operations stood at Rs 28.17 crore in Q4FY23, as against Rs 28.76 crore in Q4FY22 EBITDA for the quarter was Rs 14.93 crore as against Rs 13.08 crore in Q4FY22, increase of 14.12%. EBITDA Margin stood at 52.98%, up by 751 bps Q4FY23 PAT stood at Rs 11.69 crore as against profit of Rs 9.79 crore in Q4FY22 EPS for the quarter stood at Rs 8.05 FY23: Revenue from Operations stood at Rs 148.97 crore in FY23, vs Rs 114.85 crore in FY22, up 29.71% EBITDA for FY23 was Rs 74.22 crore as against Rs 58.05 crore in FY22, increase of 27.86% EBITDA Margin stood at 49.82% FY23 PAT stood at Rs 57.97 crore as against PAT of Rs 43.62 crore in FY22 EPS for the year stood at Rs 39.90 Result PDF
Pharmaceutical company Gujarat Themis Biosyn announced Q2FY23 results: Q2FY23 vs Q2FY22: Revenue from operations stood at Rs 47.7 crore in Q2 FY23, as against Rs 35.1 crore in Q2 FY22, rise of 36.1% EBITDA for the quarter was Rs 24.4 crore as against Rs 18.5 crore in Q2 FY22, an increase of 32.3% - EBITDA Margin stood at 51.2% Q2 FY23 Profit stood at Rs 18.7 crore as against profit of Rs 13.8 crore in Q2 FY22 EPS for the quarter stood at Rs 12.87 H1FY23 vs H1FY22: Revenue from operations stood at Rs 92.6 crore in H1 FY23, as against Rs 67.5 crore in H1 FY22, rise of 37.3% EBITDA for the six months was Rs 47.2 crore as against Rs 35.2 crore in H1 FY22, an increase of 34.2% - EBITDA Margin stood at 50.9% H1FY23 Profit stood at Rs 36.5 crore as against a profit of Rs 26.7 crore in H1 FY22 EPS for the period stood at Rs 25.10 Result PDF